Skip to main content

360o Virtual Tour360<sup>o</sup> Virtual Tour
Speak to Our Experts

At our state-of-the-art drug discovery facility for oligonucleotide synthesis, our team accelerates your early drug discovery. With years of experience in small molecules, we can design molecules, overcoming bioavailability issues, and devising a fast-forward approach for your oligo targets across therapeutic areas such as oncology, inflammation, and anti-bacterial, etc.

Our dedicated oligonucleotide platform helps to encapsulate oligonucleotide molecules for better bioavailability, and CADD trained team helps optimize the designed oligonucleotide along with primary assay iterations. We can Synthesis 10-40-mer oligonucleotide up to 1 gram scale. We can perform all standard modifications, with or without backbone modification, for which phosphoramidites are commercially available. We also have the capabilities of making any customized phosphoramidite in-house

Our Oligonucleotide synthesis services is backed by:

  • K&A H-16 automated DNA/RNA synthesizer
  • AKTA pure 25M FPLC purification system
  • Sartoflow smart TFF system for concentration and desalting
  • Martin Christ LSC plus lyophilizer with lyocube, benchtop tray lyophilizer
  • Agilent LCMS for oligonucleotide analysis
  • Implen N60 nano spectrophotometer

Aurigene Pharmaceutical Services is

a leading CDMO/CRO

that provides contract research and manufacturing services

FAQ

Oligonucleotides can be synthesized using solid-phase (Peptides) and one pot liquid phase (enzymatic) method in the lab for milligram to multi-kilogram scale. Steps involved in solid-phase Oligo synthesis are detritylation, coupling, oxidation and capping. One-pot liquid phase oligo synthesis requires polymerase enzyme, template oligonucleotide and nucleotide triphosphate as starting materials.

Accuracy of chemical synthesis of Oligonucleotides is maintained by maintaining the order of starting materials used during the synthesis process.

Oligonucleotide drugs help modulate the effect of a disease-causing gene by targeted degradation/activation of gene expression or gene editing. This activity may cause the disease to be controlled or cured.

Oligos are stable for 6 weeks in buffer when stored at 37°C and for long-term stability is to be stored between -20°C to -80°C. During storage, oligos should not be exposed to direct sunlight or UV rays.

We can Synthesis 10-40-mer oligonucleotide up to 1 gram scale.

We can perform all standard modifications, with or without backbone modification, for which Phosphoramidites are commercially available. We also have the capabilities of making any customized Phosphoramidite in-house.

For a period of 6 weeks, Oligos can be stored in T10E1 buffer at 37°C and for the long term, Oligonucleotides can be dried down and stored with or without TE buffer at -20°C.

Typical Oligonucleotide synthesis does not produce phosphate on the 5’ or 3’ end. On request, oligonucleotides can be synthesized with phosphate on the 5’ or 3’ end.

Virtual Tour

Contact Us

Country

Services Video

Resources

x

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack